Table 1.
Characteristics of the included studies
| Study | Year | Nation | Study design | Diagnosis characteristics (AO/OTA) | Implant | Gender (M/F) | Mean age (years) | Type of fracture (A1/A2/total, n) | Follow-up (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Locking | Locking | Unlocking | Unlocking | Locking | Unlocking | |||||||
| Ciaffa V | 2018 | Italy | RCT | 31-A1+ A2 | Citieffe nail | 89/50 | 77.1 ± 2.3 | 75.6 ± 3.5 | 49/24 | 46/93/139 | 25/48/73 | 12 |
| Lanzetti RM | 2018 | Italy | PCS | 31-A1+ A2 | SM Supernail | 11/57 | 84.5 ± 8.76 | 85.48 ± 7.84 | 13/62 | 38/30/68 | 35/40/75 | 14.1 (12–18). |
| Li X | 2015 | China | RCT | 31-A1 + A2 | PFNA-II | 11/24 | 78.1 ± 6.9 | 78.3 ± 7.0 | 10/25 | 7/28/35 | 11/24/35 | 12 |
| Lopez-Vega M | 2015 | Spain | RCT | 31-A1 + A2 | Gamma 3 nail | 17/73 | 84,59 ± 9,11 | 83,68 ± 6,90 | 19/68 | 34/56/90 | 46/41/87 | 12 |
| Skala-Rosenbaum | 2010 | Czech Republic | PCS | 31A1 + A2 | PFH | 10/34 | 79.6 | 79.8 | 17/57 | 14/30/44 | 38/36/74 | 12 |
| Skala-Rosenbaum J | 2016 | Czech Republic | PCS | 31A1 + A2 | PFN | N/A | N/A | 81.7 | 82.8 | NA/NA/595 | NA/NA /254 | 12 |
| V.Caiaffa | 2016 | Italy | RCT | 31-A1 + A2 | Citieffe nail | 41/89 | 78.4 ± 7.1 | 77.9 ± 7.2 | 52/84 | 37/93/130 | 48/88/136 | 12 |
| Vopat BG | 2014 | USA | RCS | 31-A1.1,+.2, +.3 | long Gamma3 | NA | NA | NA | NA | 56/0/56 | 51/0/56 | 12 |
| Yun, Ho Hyun | 2015 | Korea | RCS | 31-A1.1 + .2 | Gamma3 | 11/7 | 75.1 ± 11.7 | 75.1 ± 11.7 | 21/8 | 18/0/18 | 29/0/29 | 17.8 ± 10.6 |
RCT randomized controlled trial, PCS prospective cohort study, RCS retrospective cohort study, M/F male/female, NA notavailable